Special Issue "Photodynamic Cancer Therapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 July 2016)
Assoc. Prof. Dr. Michael R. Hamblin
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
Website | E-Mail
Phone: +1-617 726 6182
Fax: +1 617 726 6643
Interests: photodynamic therapy (PDT); low-level light therapy (LLLT); wound healing and infectious disease; atherosclerotic vulnerable plaque; anti-tumor immunity; photochemical mechanisms
Photodynamic therapy (PDT) for cancer came to prominence in 1978, in a landmark publication by Tom Dougherty regarding the use of Photofrin. Since then, hundreds of papers have presented the structures of different novel photosensitizers that could be used for anti-cancer PDT. Many investigators have dissected the signaling pathways and gene expression patterns that lead to cell death or cell survival after PDT. Nanotechnology is playing an increasingly major role in modern PDT research. Animal models allow testing of new PDT protocols, and, in the case of immunocompetent animals, also allow investigation of the anti-tumor immune response that often occurs after PDT. Clinical trials of PDT for cancer continue to be conducted and new regulatory approvals are eagerly awaited.
Prof. Dr. Michael R. Hamblin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.